Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
Identifieur interne : 000602 ( Main/Exploration ); précédent : 000601; suivant : 000603Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
Auteurs : Hanako Sekimukai [Japon] ; Naoko Iwata-Yoshikawa [Japon] ; Shuetsu Fukushi [Japon] ; Hideki Tani [Japon] ; Michiyo Kataoka [Japon] ; Tadaki Suzuki [Japon] ; Hideki Hasegawa [Japon] ; Kenichi Niikura [Japon] ; Katsuhiko Arai [Japon] ; Noriyo Nagata [Japon]Source :
- Microbiology and immunology [ 1348-0421 ] ; 2020.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (pharmacologie), Analyse de variance, Animaux, Anticorps antiviraux (immunologie), Cellules Vero, Coronavirus (immunologie), Cytokines (métabolisme), Femelle, Glycoprotéine de spicule des coronavirus (génétique), Glycoprotéine de spicule des coronavirus (immunologie), Immunisation, Immunoglobuline G (immunologie), Infections à coronavirus (), Infections à coronavirus (immunologie), Infections à coronavirus (virologie), Modèles animaux de maladie humaine, Nanoparticules métalliques (), Or (), Poumon (anatomopathologie), Poumon (immunologie), Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines recombinantes (immunologie), Récepteurs de type Toll, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Vaccination, Vaccins antiviraux (immunologie), Vaccins antiviraux (pharmacologie), Vaccins antiviraux (usage thérapeutique), Vaccins synthétiques, Virus du SRAS (immunologie).
- MESH :
- anatomopathologie : Poumon.
- génétique : Glycoprotéine de spicule des coronavirus, Protéines de l'enveloppe virale.
- immunologie : Anticorps antiviraux, Coronavirus, Glycoprotéine de spicule des coronavirus, Immunoglobuline G, Infections à coronavirus, Poumon, Protéines de l'enveloppe virale, Protéines recombinantes, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- métabolisme : Cytokines.
- pharmacologie : Adjuvants immunologiques, Vaccins antiviraux.
- usage thérapeutique : Vaccins antiviraux.
- virologie : Infections à coronavirus, Syndrome respiratoire aigu sévère.
- Analyse de variance, Animaux, Cellules Vero, Femelle, Immunisation, Infections à coronavirus, Modèles animaux de maladie humaine, Nanoparticules métalliques, Or, Récepteurs de type Toll, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Vaccination, Vaccins synthétiques.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (pharmacology), Analysis of Variance, Animals, Antibodies, Viral (immunology), Chlorocebus aethiops, Coronavirus (immunology), Coronavirus Infections (immunology), Coronavirus Infections (prevention & control), Coronavirus Infections (virology), Cytokines (metabolism), Disease Models, Animal, Female, Gold (chemistry), Immunization, Immunoglobulin G (immunology), Lung (immunology), Lung (pathology), Metal Nanoparticles (chemistry), Mice, Mice, Inbred BALB C, Recombinant Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (immunology), Toll-Like Receptors, Vaccination, Vaccines, Synthetic, Vero Cells, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Vaccines (immunology), Viral Vaccines (pharmacology), Viral Vaccines (therapeutic use).
- MESH :
- chemical , chemistry : Gold.
- chemical , genetics : Spike Glycoprotein, Coronavirus, Viral Envelope Proteins.
- chemical , immunology : Antibodies, Viral, Immunoglobulin G, Recombinant Proteins, Spike Glycoprotein, Coronavirus, Viral Envelope Proteins, Viral Vaccines.
- chemical , metabolism : Cytokines.
- chemical , pharmacology : Adjuvants, Immunologic, Viral Vaccines.
- chemistry : Metal Nanoparticles.
- immunology : Coronavirus, Coronavirus Infections, Lung, SARS Virus, Severe Acute Respiratory Syndrome.
- pathology : Lung.
- prevention & control : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- chemical , therapeutic use : Viral Vaccines.
- virology : Coronavirus Infections, Severe Acute Respiratory Syndrome.
- Analysis of Variance, Animals, Chlorocebus aethiops, Disease Models, Animal, Female, Immunization, Mice, Mice, Inbred BALB C, Toll-Like Receptors, Vaccination, Vaccines, Synthetic, Vero Cells.
Abstract
The spike (S) protein of coronavirus, which binds to cellular receptors and mediates membrane fusion for cell entry, is a candidate vaccine target for blocking coronavirus infection. However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS-CoV) induces a lung eosinophilic immunopathology upon infection. The present study evaluated two kinds of vaccine adjuvants for use with recombinant S protein: gold nanoparticles (AuNPs), which are expected to function as both an antigen carrier and an adjuvant in immunization; and Toll-like receptor (TLR) agonists, which have previously been shown to be an effective adjuvant in an ultraviolet-inactivated SARS-CoV vaccine. All the mice immunized with more than 0.5 µg S protein without adjuvant escaped from SARS after infection with mouse-adapted SARS-CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice. The AuNP-adjuvanted protein induced a strong IgG response but failed to improve vaccine efficacy or to reduce eosinophilic infiltration because of highly allergic inflammatory responses. Whereas similar virus titers were observed in the control animals and the animals immunized with S protein with or without AuNPs, Type 1 interferon and pro-inflammatory responses were moderate in the mice treated with S protein with and without AuNPs. On the other hand, the TLR agonist-adjuvanted vaccine induced highly protective antibodies without eosinophilic infiltrations, as well as Th1/17 cytokine responses. The findings of this study will support the development of vaccines against severe pneumonia-associated coronaviruses.
DOI: 10.1111/1348-0421.12754
PubMed: 31692019
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000861
- to stream PubMed, to step Curation: 000861
- to stream PubMed, to step Checkpoint: 000476
- to stream Ncbi, to step Merge: 003100
- to stream Ncbi, to step Curation: 003100
- to stream Ncbi, to step Checkpoint: 003100
- to stream Main, to step Merge: 000602
- to stream Main, to step Curation: 000602
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.</title><author><name sortKey="Sekimukai, Hanako" sort="Sekimukai, Hanako" uniqKey="Sekimukai H" first="Hanako" last="Sekimukai">Hanako Sekimukai</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tani, Hideki" sort="Tani, Hideki" uniqKey="Tani H" first="Hideki" last="Tani">Hideki Tani</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kataoka, Michiyo" sort="Kataoka, Michiyo" uniqKey="Kataoka M" first="Michiyo" last="Kataoka">Michiyo Kataoka</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Suzuki, Tadaki" sort="Suzuki, Tadaki" uniqKey="Suzuki T" first="Tadaki" last="Suzuki">Tadaki Suzuki</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Niikura, Kenichi" sort="Niikura, Kenichi" uniqKey="Niikura K" first="Kenichi" last="Niikura">Kenichi Niikura</name><affiliation wicri:level="1"><nlm:affiliation>Research Institute for Electronic Science, Hokkaido University, Sapporo, Hokkaido, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Research Institute for Electronic Science, Hokkaido University, Sapporo, Hokkaido</wicri:regionArea><wicri:noRegion>Hokkaido</wicri:noRegion></affiliation></author><author><name sortKey="Arai, Katsuhiko" sort="Arai, Katsuhiko" uniqKey="Arai K" first="Katsuhiko" last="Arai">Katsuhiko Arai</name><affiliation wicri:level="3"><nlm:affiliation>Department of Tissue Physiology, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Tissue Physiology, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:31692019</idno><idno type="pmid">31692019</idno><idno type="doi">10.1111/1348-0421.12754</idno><idno type="wicri:Area/PubMed/Corpus">000861</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000861</idno><idno type="wicri:Area/PubMed/Curation">000861</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000861</idno><idno type="wicri:Area/PubMed/Checkpoint">000476</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000476</idno><idno type="wicri:Area/Ncbi/Merge">003100</idno><idno type="wicri:Area/Ncbi/Curation">003100</idno><idno type="wicri:Area/Ncbi/Checkpoint">003100</idno><idno type="wicri:Area/Main/Merge">000602</idno><idno type="wicri:Area/Main/Curation">000602</idno><idno type="wicri:Area/Main/Exploration">000602</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.</title><author><name sortKey="Sekimukai, Hanako" sort="Sekimukai, Hanako" uniqKey="Sekimukai H" first="Hanako" last="Sekimukai">Hanako Sekimukai</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tani, Hideki" sort="Tani, Hideki" uniqKey="Tani H" first="Hideki" last="Tani">Hideki Tani</name><affiliation wicri:level="3"><nlm:affiliation>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kataoka, Michiyo" sort="Kataoka, Michiyo" uniqKey="Kataoka M" first="Michiyo" last="Kataoka">Michiyo Kataoka</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Suzuki, Tadaki" sort="Suzuki, Tadaki" uniqKey="Suzuki T" first="Tadaki" last="Suzuki">Tadaki Suzuki</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Niikura, Kenichi" sort="Niikura, Kenichi" uniqKey="Niikura K" first="Kenichi" last="Niikura">Kenichi Niikura</name><affiliation wicri:level="1"><nlm:affiliation>Research Institute for Electronic Science, Hokkaido University, Sapporo, Hokkaido, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Research Institute for Electronic Science, Hokkaido University, Sapporo, Hokkaido</wicri:regionArea><wicri:noRegion>Hokkaido</wicri:noRegion></affiliation></author><author><name sortKey="Arai, Katsuhiko" sort="Arai, Katsuhiko" uniqKey="Arai K" first="Katsuhiko" last="Arai">Katsuhiko Arai</name><affiliation wicri:level="3"><nlm:affiliation>Department of Tissue Physiology, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Tissue Physiology, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name><affiliation wicri:level="3"><nlm:affiliation>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><series><title level="j">Microbiology and immunology</title><idno type="eISSN">1348-0421</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (pharmacology)</term><term>Analysis of Variance</term><term>Animals</term><term>Antibodies, Viral (immunology)</term><term>Chlorocebus aethiops</term><term>Coronavirus (immunology)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (prevention & control)</term><term>Coronavirus Infections (virology)</term><term>Cytokines (metabolism)</term><term>Disease Models, Animal</term><term>Female</term><term>Gold (chemistry)</term><term>Immunization</term><term>Immunoglobulin G (immunology)</term><term>Lung (immunology)</term><term>Lung (pathology)</term><term>Metal Nanoparticles (chemistry)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Recombinant Proteins (immunology)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus (genetics)</term><term>Spike Glycoprotein, Coronavirus (immunology)</term><term>Toll-Like Receptors</term><term>Vaccination</term><term>Vaccines, Synthetic</term><term>Vero Cells</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (immunology)</term><term>Viral Vaccines (pharmacology)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (pharmacologie)</term><term>Analyse de variance</term><term>Animaux</term><term>Anticorps antiviraux (immunologie)</term><term>Cellules Vero</term><term>Coronavirus (immunologie)</term><term>Cytokines (métabolisme)</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus (génétique)</term><term>Glycoprotéine de spicule des coronavirus (immunologie)</term><term>Immunisation</term><term>Immunoglobuline G (immunologie)</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (virologie)</term><term>Modèles animaux de maladie humaine</term><term>Nanoparticules métalliques ()</term><term>Or ()</term><term>Poumon (anatomopathologie)</term><term>Poumon (immunologie)</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines recombinantes (immunologie)</term><term>Récepteurs de type Toll</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Vaccination</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (pharmacologie)</term><term>Vaccins antiviraux (usage thérapeutique)</term><term>Vaccins synthétiques</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Gold</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term><term>Recombinant Proteins</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Metal Nanoparticles</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Protéines de l'enveloppe virale</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Coronavirus</term><term>Glycoprotéine de spicule des coronavirus</term><term>Immunoglobuline G</term><term>Infections à coronavirus</term><term>Poumon</term><term>Protéines de l'enveloppe virale</term><term>Protéines recombinantes</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus</term><term>Coronavirus Infections</term><term>Lung</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Disease Models, Animal</term><term>Female</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Toll-Like Receptors</term><term>Vaccination</term><term>Vaccines, Synthetic</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse de variance</term><term>Animaux</term><term>Cellules Vero</term><term>Femelle</term><term>Immunisation</term><term>Infections à coronavirus</term><term>Modèles animaux de maladie humaine</term><term>Nanoparticules métalliques</term><term>Or</term><term>Récepteurs de type Toll</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccination</term><term>Vaccins synthétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The spike (S) protein of coronavirus, which binds to cellular receptors and mediates membrane fusion for cell entry, is a candidate vaccine target for blocking coronavirus infection. However, some animal studies have suggested that inadequate immunization against severe acute respiratory syndrome coronavirus (SARS-CoV) induces a lung eosinophilic immunopathology upon infection. The present study evaluated two kinds of vaccine adjuvants for use with recombinant S protein: gold nanoparticles (AuNPs), which are expected to function as both an antigen carrier and an adjuvant in immunization; and Toll-like receptor (TLR) agonists, which have previously been shown to be an effective adjuvant in an ultraviolet-inactivated SARS-CoV vaccine. All the mice immunized with more than 0.5 µg S protein without adjuvant escaped from SARS after infection with mouse-adapted SARS-CoV; however, eosinophilic infiltrations were observed in the lungs of almost all the immunized mice. The AuNP-adjuvanted protein induced a strong IgG response but failed to improve vaccine efficacy or to reduce eosinophilic infiltration because of highly allergic inflammatory responses. Whereas similar virus titers were observed in the control animals and the animals immunized with S protein with or without AuNPs, Type 1 interferon and pro-inflammatory responses were moderate in the mice treated with S protein with and without AuNPs. On the other hand, the TLR agonist-adjuvanted vaccine induced highly protective antibodies without eosinophilic infiltrations, as well as Th1/17 cytokine responses. The findings of this study will support the development of vaccines against severe pneumonia-associated coronaviruses.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Sekimukai, Hanako" sort="Sekimukai, Hanako" uniqKey="Sekimukai H" first="Hanako" last="Sekimukai">Hanako Sekimukai</name></region><name sortKey="Arai, Katsuhiko" sort="Arai, Katsuhiko" uniqKey="Arai K" first="Katsuhiko" last="Arai">Katsuhiko Arai</name><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><name sortKey="Hasegawa, Hideki" sort="Hasegawa, Hideki" uniqKey="Hasegawa H" first="Hideki" last="Hasegawa">Hideki Hasegawa</name><name sortKey="Iwata Yoshikawa, Naoko" sort="Iwata Yoshikawa, Naoko" uniqKey="Iwata Yoshikawa N" first="Naoko" last="Iwata-Yoshikawa">Naoko Iwata-Yoshikawa</name><name sortKey="Kataoka, Michiyo" sort="Kataoka, Michiyo" uniqKey="Kataoka M" first="Michiyo" last="Kataoka">Michiyo Kataoka</name><name sortKey="Nagata, Noriyo" sort="Nagata, Noriyo" uniqKey="Nagata N" first="Noriyo" last="Nagata">Noriyo Nagata</name><name sortKey="Niikura, Kenichi" sort="Niikura, Kenichi" uniqKey="Niikura K" first="Kenichi" last="Niikura">Kenichi Niikura</name><name sortKey="Suzuki, Tadaki" sort="Suzuki, Tadaki" uniqKey="Suzuki T" first="Tadaki" last="Suzuki">Tadaki Suzuki</name><name sortKey="Tani, Hideki" sort="Tani, Hideki" uniqKey="Tani H" first="Hideki" last="Tani">Hideki Tani</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000602 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000602 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31692019
|texte= Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31692019" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |